• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Genmab A/S

    2/12/25 4:43:37 PM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMAB alert in real time by email
    S-8 1 ss4443496_s8.htm REGISTRATION STATEMENT

     

     

    As filed with the Securities and Exchange Commission on February 12, 2025

    Registration No. 333-

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

    GENMAB A/S
    (Exact name of registrant as specified in its charter)

    The Kingdom of Denmark

    (State or other jurisdiction of incorporation or organization)

    Carl Jacobsens Vej 30

    2500 Valby

    Denmark

    (Address of Principal Executive
    Offices, including zip code)

    Not Applicable

    (I.R.S. Employer
    Identification No.)

     

    Genmab A/S 2021 Restricted Stock Units Program
    Genmab A/S 2021 Warrant Scheme
    (Full title of the plans)

    Genmab US, Inc.
    777 Scudders Mill Road
    Plainsboro, NJ 08536
    (Name and address of agent for service)
    (609) 430-2481
    (Telephone number, including area code, of agent for service)

    With a copy to:
    Doreen E. Lilienfeld, Esq.
    Allen Overy Shearman Sterling, LLP
    599 Lexington Avenue
    New York, NY 10022
    (212) 848-4000

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☒ Accelerated filer ☐
           
    Non-accelerated filer ☐ Smaller reporting company ☐
           
        Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ❑

     

     

     

     
     

     

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    All information required by Part I of Form S-8 to be contained in the prospectus is omitted from this Registration Statement on form S-8 (the “Registration Statement”) in accordance with Rule 428 under the Securities Act and the “Note” to Part I of Form S-8.

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3.Incorporation of Documents by Reference.

     

    The following documents filed with the Securities and Exchange Commission (the “Commission”) are hereby incorporated by reference in this Registration Statement:

    (a) The Registrant’s annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the Commission on February 12, 2025.

    (b) All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act, since the end of the fiscal year covered by the registration statement referred to in (a) above (other than portions of those documents furnished or not otherwise deemed to be filed).

    (c) The description of the Registrant’s Ordinary Shares and American Depositary Shares incorporated by reference to Exhibit 2.3 to the Registrant’s annual report on Form 20-F filed with the Commission on February 12, 2025.

    All documents filed by the Registrant subsequent to the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act and, to the extent specifically designated therein, Reports of Foreign Private Issuer on Form 6-K furnished by the Registrant to the Commission that are identified in such forms as being incorporated into this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement indicating that all of the securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be part hereof from the date of filing such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     
     

     

    Item 4.Description of Securities.

     

    Not applicable

    Item 5.Interests of Named Experts and Counsel.

     

    Not applicable

    Item 6.Indemnification of Directors and Officers.

     

    According to the Danish Companies Act, shareholders, at the general meeting, are permitted to discharge the Registrant’s board members and registered managers from liability for any particular financial year based on a resolution relating to the period covered by the financial statements for the previous financial year. This discharge means that the shareholders will relieve such board members and registered managers from liability to the Registrant. However, shareholders cannot discharge any claims by individual shareholders or other third parties. The discharge can be set aside in case the general meeting prior to its decision to discharge was not presented with all reasonable information necessary for the general meeting to assess the matter at hand. In addition, the Registrant provides its board members and registered managers with directors’ and officers’ liability insurance.

    Item 7.Exemption from Registration Claimed.

     

    Not applicable.

    Item 8.Exhibits.

     

    The following exhibits are filed as part of this Registration Statement:

    Exhibit Number

    Description of Document

    4.1 English translation of the Articles of Association of Genmab A/S, as in effect on the date hereof, filed as Exhibit 3.1 to the Registrant’s Current Report on Form 6-K filed with the Commission on December 4, 2024 (File No. 001-38976)
    4.2 Genmab A/S 2021 Restricted Stock Units Program (incorporated by reference to Exhibit 4.2 to the Registrant’s Registration Statement on Form S-8, filed with the Commission on February 25, 2021 (File No. 333-253519))
    5.1* Opinion of Kromann Reumert, with respect to the legality of the securities being registered
    23.1* Consent of Kromann Reumert (included in the opinion filed as Exhibit 5.1)
    23.2* Consent of Deloitte Statsautoriseret Revisionspartnerselskab
    24.1* Limited Power of Attorney of the directors of the Registrant (contained in the signature pages hereto)
    99.1 Genmab A/S 2021 Warrant Scheme (incorporated by reference to Exhibit 99.1 to the Registrant’s Registration Statement on Form S-8, filed with the Commission on February 25, 2021 (File No. 333-253519))
    107* Filing Fee Table

    _____________

    * Filed herewith.

    Item 9.Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made of securities registered hereby, a post-effective amendment to this Registration Statement which shall include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     
     

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration Statement; and 

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or any material change to such information in this Registration Statement; provided, however, that paragraphs (1)(i) and (1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof; and

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby further undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. 

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. 

    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Utrecht, the Netherlands on February 11, 2025.

      Genmab A/S
      (Registrant)
      By: /s/ Jan G. J. van de Winkel
        Jan G. J. van de Winkel
        President & Chief Executive Officer

     

     

     
     

     

     

    Limited Power of Attorney
    (Form S-8)

    KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned officers and directors of the Registrant does hereby constitute and appoint each of Birgitte Stephensen and Anthony Pagano as his or her true and lawful attorney-in-fact and agent, to do or cause to be done any and all acts and things and to execute any and all instruments and documents which said attorneys-in-fact and agents may deem advisable or necessary to enable the Company to comply with the Securities Act, and any rules, regulations and requirements of the Commission in respect thereof, in connection with the registration of the securities or deferred compensation obligations of the Registrant being registered on the Registration Statement (the “Securities”), including specifically, but without limiting the generality of the foregoing, power and authority to sign, in the name and on behalf of each of the undersigned, the Registration Statement, any other registration statement under Rule 462(b) of the Securities Act, or another appropriate form in respect of the registration of the Securities, and any and all amendments thereto, including post-effective amendments, and any instruments, contracts, documents or other writings of which the originals or copies thereof are to be filed as a part of, or in connection with, any such registration statement or any other appropriate form or amendments thereto, and to file or cause to be filed the same with the Commission, and to effect any and all applications and other instruments in the name and on behalf of each of the undersigned which said attorneys-in-fact and agents deem advisable in order to qualify or register the Securities under the securities laws of any of the several states or other jurisdictions; and each of the undersigned does hereby ratify all that said attorneys-in-fact and agents shall do or cause to be done by virtue thereof. Each attorney-in-fact and agent is hereby granted full power of substitution and revocation with respect hereto.

     

    Signatures Title Date
         
    /s/ Jan G. J. van de Winkel    
    Jan G. J. van de Winkel President & Chief Executive Officer February 11, 2025
      (Principal Executive Officer)  
         
    /s/ Anthony Pagano    
    Anthony Pagano Executive Vice President & Chief Financial Officer February 11, 2025
      (Principal Financial Officer and Principal Accounting  
      Officer)  
         
    /s/ Deirdre P. Connelly    
    Deirdre P. Connelly Chair of the Board of Directors February 11, 2025
         
         
    /s/ Pernille Erenbjerg    
    Pernille Erenbjerg Deputy Chair of the Board of Directors February 11, 2025
         
    /s/ Anders Gersel Pedersen    
    Anders Gersel Pedersen Director February 11, 2025
         
    /s/ Paolo Paoletti    
    Paolo Paoletti Director February 11, 2025
         
    /s/ Rolf Hoffman    
    Rolf Hoffman Director February 11, 2025
         
    /s/ Elizabeth O’Farrell    
    Elizabeth O’Farrell Director February 11, 2025
         
    /s/ Mijke Zachariasse    
    Mijke Zachariasse Director February 11, 2025
         
    /s/ Takahiro Hamatani    
    Takahiro Hamatani Director February 11, 2025
         
    /s/ Martin Schultz    
    Martin Schultz Director February 11, 2025

     

     
     

     

    IN WITNESS WHEREOF, each of the undersigned has executed this Limited Power of Attorney as of and on the dates indicated below. 

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

      

    Signature of Authorized U.S. Representative of Registrant

    Pursuant to the requirements of the Securities Act, the undersigned, the duly authorized representative in the United States of the Registrant, has signed this Registration Statement on February 11, 2025.

      By: /s/ Anthony Pagano
        Name: Anthony Pagano
        Title: Executive Vice President and Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     
    Get the next $GMAB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GMAB

    DatePrice TargetRatingAnalyst
    4/1/2025Mkt Perform → Underperform
    Bernstein
    3/11/2025Mkt Perform → Outperform
    William Blair
    2/13/2025$27.00Market Perform → Outperform
    Leerink Partners
    10/8/2024Buy
    Redburn Atlantic
    9/4/2024$31.00Equal-Weight
    Morgan Stanley
    8/20/2024Overweight → Neutral
    JP Morgan
    7/15/2024Sector Perform → Outperform
    RBC Capital Mkts
    2/23/2024$46.00 → $48.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $GMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Genmab downgraded by Bernstein

      Bernstein downgraded Genmab from Mkt Perform to Underperform

      4/1/25 9:01:35 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab upgraded by William Blair

      William Blair upgraded Genmab from Mkt Perform to Outperform

      3/11/25 7:35:51 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Genmab from Market Perform to Outperform and set a new price target of $27.00

      2/13/25 7:09:15 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

      Company Announcement Net sales of DARZALEX® in the second quarter of 2025 totaled USD 3,539 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,539 million in the second quarter of 2025. Net trade sales were USD 2,017 million in the U.S. and USD 1,521 million in the rest of the world. Genmab receives royalties on the w

      7/16/25 6:29:31 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Completion of Share Buy-back Program

      Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (NASDAQ:GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program was expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 23, 2025, to June 26, 2025:  Trading PlatformNo. of sharesAverage price (DKK)Total Value (DKK)Accumulated through last announcement 2,081,211 2,707,132,655.69June 23, 2025XCSE

      6/30/25 9:29:47 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Transactions in Connection with Share Buy-back Program

      Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (NASDAQ:GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program. The share buy-back program is expected to be completed no later than July 10, 2025. The following transactions were executed under the program from June 16 to June 20, 2025:  Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 2,080,711 2,706,417,889.19June 16, 2025XCSE1001,477.73147,772.50 BCXE0   AQEU0   TQEX0   Total100 147,772.50June 17, 2025XCSE1001,

      6/23/25 8:19:15 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    SEC Filings

    See more
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      7/16/25 7:15:41 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Genmab A/S

      EFFECT - GENMAB A/S (0001434265) (Filer)

      7/16/25 12:15:12 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      6/30/25 10:38:37 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Financials

    Live finance-specific insights

    See more
    • Capital Increase in Genmab as a Result of Employee Warrant Exercise

      Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (NASDAQ:GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 27,396 shares at DKK 1,025.00,2,790 shares at DKK 1,050.00, 150 shares at DKK 1,147.50,1,557 shares at DKK 1,161.00, and224 shares at DKK 1,334.50. Proceeds to the company are approximately DKK 33.3 million. The increase corresponds to approximately 0.05% of the company's share capital. The new shares are ord

      6/17/25 1:34:35 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

      Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38 Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a

      3/10/25 10:21:00 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

      Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT COPENHAGEN, Denmark; March 10, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising

      3/10/25 10:13:07 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

      Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera

      2/22/21 8:00:51 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Genmab A/S (Amendment)

      SC 13G/A - GENMAB A/S (0001434265) (Subject)

      2/8/24 10:03:08 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Genmab A/S (Amendment)

      SC 13G/A - GENMAB A/S (0001434265) (Subject)

      2/2/24 2:18:06 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genmab A/S

      SC 13G - GENMAB A/S (0001434265) (Subject)

      2/6/23 2:36:15 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care